LENVIMA (lenvatinib) capsules

By :

New Ebola Vaccine for Exposure Risk

NEW DRUG: LENVIMA Company: Eisai Approval Status: Approved February 2015 Specific Treatments: Differentiated thyroid cancer (DTC) Therapeutic Areas: Oncology Lenvima tablet was approved by FDA based on a multicenter, randomized, double-blind, placebo-controlled trial in 392 patients with locally recurrent or metastatic radioactive iodine-refractory differentiated thyroid cancer and radiographic evidence of disease progression within 12 months prior to randomization, confirmed by independent radiologic review. The subjects received LENVIMA 24 mg once daily (n=261) or placebo (n=131) until disease progression. Continue LENVIMA until disease progression or until unacceptable toxicity occurs. Lenvima is specifically indicated for the treatment of locally recurrent or metastatic, progressive, radioactive iodine-refractory differentiated thyroid cancer. Lenvima (lenvatinib) is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. A single 32 mg dose (1.3 times the recommended daily dose) of lenvatinib did not prolong the QT/QTc interval in a thorough QT study in healthy subjects. However, QT prolongation was observed. Absorption: After oral administration of LENVIMA, time to peak plasma concentration (Tmax) typically occurred from 1 to 4 hours post-dose. Administration with food did not affect the extent of absorption, but decreased the rate of absorption and delayed the median Tmax from 2 hours to 4 hours Distribution: In vitro binding of lenvatinib to human plasma proteins ranged from 98% to 99% (0.3 – 30 μg/mL). In vitro, the lenvatinib blood-to-plasma concentration ratio ranged from 0.589 to 0.608 (0.1 – 10 μg/mL). Elimination: Plasma concentrations declined bi-exponentially following Cmax. The terminal elimination half-life of lenvatinib was approximately 28 hours. Metabolism: CYP3A is one of the main metabolic enzymes of lenvatinib. Excretion: Ten days after a single administration of radiolabeled lenvatinib to 6 patients with solid tumors, approximately 64% and 25% of the radiolabel were eliminated in the feces and urine, respectively. DRUG INTERACTIONS: No dose adjustment of LENVIMA is recommended when co-administered with CYP3A, Pglycoprotein (P-gp), and breast cancer resistance protein (BCRP) inhibitors and CYP3A and P-gp inducers Effect of Lenvatinib on Other Drugs CYP3A4 or CYP2C8 Substrates: There is no projected significant drug-drug interaction risk between lenvatinib and midazolam (a CYP3A4 substrate) or repaglinide (a CYP2C8 substrate). Information by : Ms. Sahitya Kurapati #health #research #thyroidcancer #LENVIMA #cancer #DrSahityaKurapati #healthcare #drug #lifestyle
Rate UsDon’t love itNot greatGoodGreatLove itRate Us
Your opinion
arrow&v
arrow&v

PHAF DIC Team

Approval of new treatment for adults with partial-onset seizures

PHAF Team

Navigating the New Clozapine REMS

PHAF Team

LENVIMA (lenvatinib) capsules

PHAF Team

FDA approval : first treatment for frequent urination at night

PHAF Team

A new eczema drug Dupixent : FDA Approval

PHAF Team

New drug that can prevent breast cancer growth identified

© 2019 PHAF  || All rights reserved

  • Facebook Social Icon
  • Twitter Social Icon
  • Google+ Social Icon
  • YouTube Social  Icon
  • Instagram Social Icon

Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a healthcare professional.